UBS Group Cuts Boston Scientific (NYSE:BSX) Price Target to $105.00

Boston Scientific (NYSE:BSX) had its price target reduced by UBS Group from $120.00 to $105.00 in a research note published on Tuesday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

BSX has been the topic of several other research reports. Truist Financial reduced their price target on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Robert W. Baird lowered their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Oppenheimer cut their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, Canaccord Genuity Group decreased their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $107.18.

Boston Scientific Stock Performance

Shares of BSX opened at $70.04 on Tuesday. The firm has a market cap of $103.93 billion, a price-to-earnings ratio of 36.10, a PEG ratio of 1.00 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average is $80.31 and its two-hundred day moving average is $92.40. Boston Scientific has a 52-week low of $67.56 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Large investors have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in Boston Scientific during the 4th quarter valued at $2,199,395,000. Edgewood Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth $746,655,000. Parnassus Investments LLC grew its stake in shares of Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP increased its holdings in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the period. Finally, Maverick Capital Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter valued at $280,735,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts still show support: Truist trimmed its price target (from $95 to $92) but kept a “buy” rating, signaling continued conviction in BSX’s medium?term upside. Truist lowers price target
• Positive Sentiment: Market commentary highlights Boston Scientific as a defensive, highly rated healthcare stock—helpful positioning if macro/commodity volatility rises. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Broader health?care weakness: the NYSE Health Care Index was softer late Thursday, weighing on names including BSX. Sector Update: Health Care Stocks Softer
• Neutral Sentiment: Relative underperformance note: MarketWatch flagged BSX as underperforming peers during the session, which can amplify selling flows even absent company?specific new data. Boston Scientific Corp. stock underperforms Thursday
• Negative Sentiment: Recall expanded: Boston Scientific amended its Accolade pacemaker recall; the affected population is now ~1.6 million devices — a clear near?term operational and reputational headwind. Market Chatter: Boston Scientific Amends Recall
• Negative Sentiment: Investigative report: The New York Times reports Boston Scientific knew of pacemaker battery problems for years and an internal 2025 test found extremely high failure rates — this raises potential regulatory, replacement, and liability risks. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Legal overhang: multiple securities?class?action complaints and numerous law?firm investor alerts have surfaced, creating ongoing litigation risk and potential settlements/expenses. Rosen Law Firm investor alert
• Negative Sentiment: Street view trimmed: UBS lowered expectations for BSX, adding to the negative analyst chatter that can pressure sentiment. UBS lowers expectations

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.